Table 4.
HRs with 95% CIs for the primary outcomes of death, all-cause allograft failure, and allograft failure excluding death as a cause (competing risks model), by cause of ESRD, n=107,778
| Outcome | Primary GN Subtypes | Secondary GN Subtypes | Non-GN Comparator Groups | |||||
|---|---|---|---|---|---|---|---|---|
| FSGS n=13,272 | IgAN n=7379 | MN n=2249 | MPGN n=1980 | LN n=5884 | Vasculitis n=1367 | DN n=57,190 | ADPKD n=18,457 | |
| Death | ||||||||
| Model 1 | 2.10 | Ref | 2.56 | 2.29 | 2.09 | 2.76 | 5.36 | 2.06 |
| (2.04 to 2.16) | (2.46 to 2.66) | (2.20 to 2.39) | (2.02 to 2.16) | (2.63 to 2.89) | (5.22 to 5.50) | (2.01 to 2.12) | ||
| Model 2 | 1.70 | Ref | 1.64 | 1.95 | 2.15 | 1.73 | 3.43 | 1.29 |
| (1.55 to 1,87) | (1.45 to 1.86) | (1.71 to 2.22) | (1.94 to 2.39) | (1.50 to 2.01) | (3.15 to 3.73) | (1.18 to 1.41) | ||
| Model 3 | 1.57 | Ref | 1.53 | 1.77 | 1.84 | 1.56 | 2.61 | 1.26 |
| (1.43 to 1.73) | (1.35 to 1.73) | (1.55 to 2.01) | (1.65 to 2.04) | (1.34 to 1.81) | (2.38 to 2.86) | (1.15 to 1.38) | ||
| Model 4 | 1.57 | Ref | 1.52 | 1.76 | 1.82 | 1.56 | 2.57 | 1.22 |
| (1.43 to 1.72) | (1.34 to 1.72) | (1.55 to 2.01) | (1.63 to 2.02) | (1.34 to 1.81) | (2.35 to 2.82) | (1.12 to 1.34) | ||
| All-cause allograft failure | ||||||||
| Model 1 | 1.76 | Ref | 1.74 | 1.91 | 1.69 | 1.47 | 2.43 | 1.13 |
| (1.73 to 1.80) | (1.69 to 1.78) | (1.86 to 1.97) | (1.65 to 1.73) | (1.42 to 1.52) | (2.39 to 2.47) | (1.11 to 1.16) | ||
| Model 2 | 1.44 | Ref | 1.36 | 1.68 | 1.48 | 1.16 | 1.90 | 0.97 |
| (1.36 to 1.53) | (1.24 to 1.48) | (1.54 to 1.83) | (1.38 to 1.58) | (1.03 to 1.30) | (1.80 to 2.00) | (0.91 to 1.03) | ||
| Model 3 | 1.36 | Ref | 1.29 | 1.56 | 1.33 | 1.04 | 1.69 | 0.96 |
| (1.28 to 1.44) | (1.18 to 1.40) | (1.42 to 1.70) | (1.24 to 1.43) | (0.93 to 1.17) | (1.59 to 1.79) | (0.90 to 1.02) | ||
| Model 4 | 1.34 | Ref | 1.26 | 1.52 | 1.32 | 1.06 | 1.63 | 0.93 |
| (1.26 to 1.42) | (1.15 to 1.38) | (1.40 to 1.66) | (1.23 to 1.42) | (0.95 to 1.19) | (1.54 to 1.74) | (0.88 to 0.99) | ||
| Allograft failure with death as a competing risk | ||||||||
| Model 1 | 1.59 | Ref | 1.42 | 1.79 | 1.59 | 0.98 | 1.19 | 0.76 |
| (1.49 to 1.71) | (1.28 to 1.57) | (1.62 to 1.98) | (1.47 to 1.72) | (0.85 to 1.14) | (1.12 to 1.27) | (0.71 to 0.81) | ||
| Model 2 | 1.30 | Ref | 1.36 | 1.62 | 1.15 | 0.97 | 1.17 | 0.88 |
| (1.21 to 1.39) | (1.23 to 1.51) | (1.46 to 1.79) | (1.06 to 1.24) | (0.84 to 1.13) | (1.10 to 1.25) | (0.81 to 0.94) | ||
| Model 3 | 1.24 | Ref | 1.32 | 1.56 | 1.11 | 0.90 | 1.24 | 0.89 |
| (1.16 to 1.33) | (1.19 to 1.47) | (1.41 to 1.72) | (1.03 to 1.21) | (1.78 to 1.05) | (1.15 to 1.33) | (0.82 to 0.95) | ||
| Model 4 | 1.20 | Ref | 1.27 | 1.50 | 1.11 | 0.94 | 1.16 | 0.85 |
| (1.12 to 1.28) | (1.14 to 1.41) | (1.36 to 1.66) | (1.02 to 1.20) | (0.81 to 1.09) | (1.08 to 1.25) | (0.79 to 0.91) | ||
Model 1, stratified by year of transplantation. Model 2, added sociodemographic variables: age, age*age, sex, race, ethnicity, geographic region, insurance type, college. Model 3, added dialysis modality, dialysis vintage, comorbidities (unable to ambulate, coronary heart disease, cancer, congestive heart failure, COPD, CVA/TIA, diabetes, hypertension, current/recent smoker, PVD), BMI group, HCV status. Model 4, added transplant-related variables: ABO blood group, CIT, donor age, donor sex, donor race, HLA mismatch group, donor type (living/decreased/expanded criteria), PPRA, initial post-transplant immunosuppression (Alemtuzumab, Basiliximab, Daclizumab, or Thymoglobulin induction; Tacrolimus, Ciclosporin, Sirolimus, MMF, Azathioprine and/or steroid maintenance), previous blood transfusion, DGF. DN, diabetic nephropathy; Ref, reference; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; TIA, transient ischemic attack; PVD, peripheral vascular disease; BMI, body mass index; CIT, cold ischemia time; HLA, histocompatibility leukocyte antigen; PPRA, peak panel reactive antibody; MMF, mycophenolate mofetil.